Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Krebs Biochemicals & Industries Limited is an Indian specialty pharmaceutical manufacturer focused on active pharmaceutical ingredients (APIs) and intermediates, primarily serving domestic and export markets. The company operates in a capital-intensive segment with high gross margins but is currently experiencing severe operational losses, negative cash flow, and deteriorating financial health with a current ratio of 0.09 indicating acute liquidity stress.
Krebs operates as a B2B supplier manufacturing complex chemical compounds and APIs through multi-step synthesis processes. The 87.2% gross margin suggests high-value specialty products with significant technical barriers, but the -50.1% operating margin indicates severe overhead burden, underutilized capacity, or operational inefficiencies. Revenue is typically driven by long-term supply contracts with pharmaceutical companies, with pricing influenced by raw material costs (primarily petrochemical-derived solvents and reagents), regulatory compliance costs, and competitive intensity from Chinese and Indian API manufacturers. The business model requires substantial working capital for inventory and receivables, which appears critically strained given the 0.09 current ratio.
New API product approvals and regulatory certifications (USFDA, EUGMP) that open export markets
Raw material cost inflation, particularly petrochemical-derived solvents and specialty chemicals that compress margins
Working capital management and liquidity events - with 0.09 current ratio, any debt restructuring or capital raise would be material
Customer concentration risk - loss or gain of major pharmaceutical clients significantly impacts revenue
Chinese API pricing dynamics - Chinese manufacturers dominate global API supply and set competitive pricing benchmarks
Chinese API manufacturing dominance - Chinese producers have cost advantages through scale, vertical integration, and government support, creating persistent pricing pressure on Indian manufacturers
Regulatory compliance costs - Escalating quality standards from USFDA, EUGMP, and other regulators require continuous capital investment that the company cannot currently afford
Environmental regulations - API manufacturing generates hazardous waste; stricter environmental norms in India increase compliance costs and may require facility upgrades
Commoditization of API portfolio - If Krebs produces standard APIs rather than complex specialty molecules, pricing power erodes rapidly as patents expire and competition intensifies
Customer backward integration - Large pharmaceutical companies increasingly manufacture their own APIs to control costs and supply chains, reducing addressable market
Imminent liquidity crisis - 0.09 current ratio indicates the company cannot meet short-term obligations with current assets; bankruptcy or distressed restructuring risk is elevated
Negative equity position - Debt/equity of -1.39 suggests liabilities exceed assets, indicating potential insolvency without immediate capital infusion or debt forgiveness
Negative operating cash flow of $0.1B with minimal capex suggests the business is consuming cash in core operations, unsustainable without external financing
moderate - Pharmaceutical demand is relatively non-cyclical as healthcare spending persists through economic cycles, but API manufacturers face cyclical pressures from customer destocking, generic drug pricing erosion, and deferred capacity expansions by pharmaceutical clients during downturns. The company's export exposure creates sensitivity to global pharmaceutical market conditions and currency fluctuations.
Rising interest rates significantly pressure Krebs through multiple channels: (1) higher financing costs on working capital facilities and debt refinancing given the distressed balance sheet, (2) reduced valuation multiples for unprofitable growth companies, and (3) stronger USD making Indian exports less competitive. With negative cash flow and acute liquidity stress, access to affordable capital is critical.
High - The company's survival depends on continued access to working capital financing and potential debt restructuring. With -1.39 debt/equity ratio (suggesting negative equity), 0.09 current ratio, and negative operating cash flow, credit conditions are paramount. Tightening credit markets or rising risk premiums in Indian corporate debt would severely constrain operations or force dilutive equity raises.
Distressed/special situations investors - The company exhibits characteristics of a turnaround or restructuring candidate with high gross margins but severe operational and financial distress. Not suitable for traditional growth, value, or income investors given negative profitability, negative cash flow, and balance sheet stress. Only appropriate for investors with high risk tolerance seeking asymmetric returns from potential operational turnaround or asset recovery in bankruptcy scenarios.
high - Stock has declined 29.2% over one year with accelerating losses in recent quarters. Distressed financials, liquidity concerns, and potential restructuring events create extreme volatility. Small market cap ($1.3B) and likely low trading liquidity amplify price swings on any news.